Combination Therapy for Dyslipidemia
Combination Therapy for Dyslipidemia
Combination therapy is often utilized in the management of dyslipidemia to achieve better lipid control and reduce the risk of cardiovascular disease.
Specific drug combinations have been proven advantageous while other combinations should be avoided.
Important Considerations:
Avoided Combinations:
Gemfibrozil and Statins: This combination is contraindicated due to the risk of rhabdomyolysis, a serious condition that can lead to kidney damage.
Resins or Bile Acid Sequestrants: These can interfere with the absorption of statins (HMG-CoA reductase inhibitors).
Therefore, it is recommended that statins be administered at least 1 hour before or 4 hours after taking the resins to prevent absorption issues.
Risks with Some Combinations:
Combinations of HMG-CoA reductase inhibitors with fibrates or niacin may increase the likelihood of developing myopathy or myositis, conditions characterized by muscle inflammation, which can escalate to rhabdomyolysis.
Combination Therapy for Dyslipidemia Table 35-1
Condition/Cause | Manifestations, Cause | Single Drug | Drug Combination |
|---|---|---|---|
Primary chylomicronemia | Chylomicrons, VLDL increased; deficiency in LPL or apoC-II | Dietary management (omega-3 fatty acids, niacin, or fibrate) | Niacin plus fibrate |
Familial hypertriglyceridemia - Severe | VLDL, chylomicrons increased; decreased clearance of VLDL | Omega-3 fatty acids, niacin or fibrate | Niacin plus fibrate |
Familial hypertriglyceridemia - Moderate | VLDL increased, chylomicrons may be increased; increased production of VLDL | Omega-3 fatty acids, niacin or fibrate | |
Familial combined hyperlipoproteinemia | Increased hepatic apoB and VLDL production; VLDL increased; LDL increased; VLDL increased, LDL increased | Omega-3 fatty acids, niacin, fibrate, statin Niacin, statin, ezetimibe Omega-3 fatty acids, niacin, statin | Two or 3 of the individual drugs Two or 3 of the individual drugs Niacin or fibrate plus statin |
Familial dysbetalipoproteinemia | VLDL remnants, chylomicron remnants increased; deficiency in apoE | Omega-3 fatty acids, fibrate, niacin | Fibrate plus niacin, or either plus statin |
Familial hypercholesterolemia Heterozygous Homozygous | LDL increased; defect in LDL receptors | Statin, resin, niacin, ezetimibe Niacin, atorvastatin, rosuvastatin, ezetimibe | Two or 3 of the individual drugs Niacin plus statin plus ezetimibe |
Note: Single-drug therapy with a marine omega-3 dietary supplement should be evaluated before the initiation of drug combinations, as lifestyle modifications and dietary strategies often play a crucial role in managing dyslipidemia effectively.